

## Hepatology COVID-19 Registry Week 16 Report

## 5 new cases added to the report since week 15


	Liver disease, Non-Transplant (N=28)	Post-liver transplantation (N=27)
Gender (%)	Female = 10 (36%)	Female = 14 (51.9 %)
	Male = 18 (64%)	Male = 13 (48.1 %)
Median Age (yr) at time of COVID	8 (0.16-20)	13 (0.5-21)
diagnosis (range)		
Etiology of liver disease	Biliary atresia = 7	Biliary atresia = 9
	NAFLD = 7	Acute liver failure = 6
	Autoimmune hepatitis = 5	Metabolic disorders = 3
	Acute Liver Failure = 2	Tumor = 2
	Metabolic disorder = 2	Others** = 7
	Others* = 5	
Highest level of care		
Outpatient	7	19
Hospital floor	11	5
ICU	10	4
Immunosuppression at time	No Immunosuppression = 21	Tacrolimus = 23
of COVID diagnosis	Azathioprine = 5	Steroids = 10
(*some patients were on multiple	Steroids =3	Mycophenolate Mofetil = 9
agents)		Sirolimus = 3
		Azathioprine = 2
		Cyclosporine =1
Specific Treatment for COVID	Hydroxychloroquine + Azithromycin = 4	Hydroxychloroquine = 2
(*some patients were on multiple	IVIG = 4	Azithromycin = 1
agents)	Remdesivir = 4	IVIG = 1
	Steroids = 3	Favipiravir = 1
	Tocilizumab + Sarilumab = 2	Convalescent Plasma = 2
	Eculizimab = 2	Remdesivir = 1
	Convalescent Plasma = 1	Steroid (Dexamethasone) = 1
	Anakinra = 1	
	Hydroxychloroquine = 1	
Highest respiratory support		
None	18	24
Nasal cannula/CPAP/BiPAP	5	2
Mechanical ventilation	4	0
High Frequency Oscillatory	1	0
ventilation		
Pending information	-	1
Final clinical outcome		1
Death	1***	0
Recovery	24	23
Still active in clinical course	2	3
Pending information	1	1
Liver related Complications	Ascites = 7	Infection = 1
and the second second	Portal Hypertension Bleeding =1	
	Infection = 1	
4-1 11 11 1	estasis GVHD (vanishing hile dust sundrame (Bost BMT) IEALD	

\*Others CLD: idiopathic cholestasis, GVHD/vanishing bile duct syndrome (Post BMT), IFALD with biliary obstruction, PFIC

\*\* Others PLT: IFALD, Congenital hepatic fibrosis, AIH-Sclerosing cholangitis, Cryptogenic


\*\*\*Pulmonary hemorrhage, multi-organ failure

## Presenting symptoms at time of diagnosis



<sup>\*</sup>Constitutional symptoms reported: Loss of smell/taste , fever, myalgia, fatigue, sore throat # Other symptoms reported: Malaise, anorexia, headache, rash, Kawasaki disease like presentation(MIS-C)

## Change done to Immunosuppressive agent (Post LT)



<sup>\*</sup>Stopped, decreased the dose, others and No changes Commonest agent **stopped**: Mycophenolate Mofetil